Literature DB >> 19301406

Fertility preservation medicine: a new field in the care of young cancer survivors.

Kutluk Oktay1, Ozgur Oktem.   

Abstract

Treatment modalities for numerous oncological and non-oncological conditions result in gonadal insufficiency and infertility. Furthermore, pelvic-abdominal radiation may result in uterine damage resulting in poor reproductive outcomes such as preterm birth, low birth weight, and spontaneous abortion in adult survivors of childhood cancers. In response to the recognition of the impact of cancer treatments on fertility, several fertility preservation techniques have been developed. In prepubertal children, fertility preservation options are usually limited to ovarian cryopreservation because of sexual immaturity, but oocyte freezing can be performed in adolescent children. Two prospective randomized studies showed no benefit of gonadal suppression with GnRH analogs to preserve gonadal function and thus this treatment should not be recommended. For adult survivors of childhood cancer who experienced reproductive failure, third party reproduction techniques are highly successful. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301406     DOI: 10.1002/pbc.22003

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

1.  Fertility Preservation for Prepubertal Girls: Update and Current Challenges.

Authors:  Nina Resetkova; Masanori Hayashi; Lisa A Kolp; Mindy S Christianson
Journal:  Curr Obstet Gynecol Rep       Date:  2013-12-01

Review 2.  Applicability of adult techniques for ovarian preservation to childhood cancer patients.

Authors:  Laura Detti; Daniel C Martin; Lucy J Williams
Journal:  J Assist Reprod Genet       Date:  2012-07-21       Impact factor: 3.412

3.  Ovarian tissue cryopreservation in girls undergoing haematopoietic stem cell transplant: experience of a single centre.

Authors:  E Biasin; F Salvagno; M Berger; F Nesi; P Quarello; E Vassallo; F Evangelista; G L Marchino; A Revelli; C Benedetto; F Fagioli
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

Review 4.  Development of a Pediatric Fertility Preservation Program: A Report From the Pediatric Initiative Network of the Oncofertility Consortium.

Authors:  Molly B Moravek; Leslie C Appiah; Antoinette Anazodo; Karen C Burns; Veronica Gomez-Lobo; Holly R Hoefgen; Olivia Jaworek Frias; Monica M Laronda; Jennifer Levine; Lillian R Meacham; Mary Ellen Pavone; Gwendolyn P Quinn; Erin E Rowell; Andrew C Strine; Teresa K Woodruff; Leena Nahata
Journal:  J Adolesc Health       Date:  2019-01-14       Impact factor: 5.012

Review 5.  Ovarian and Uterine Functions in Female Survivors of Childhood Cancers.

Authors:  Ozgur Oktem; Samuel S Kim; Ugur Selek; Glenn Schatmann; Bulent Urman
Journal:  Oncologist       Date:  2017-11-20

6.  Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.

Authors:  Elon C Roti Roti; Scott K Leisman; David H Abbott; Sana M Salih
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

7.  Reproductive late effects in female survivors of childhood cancer.

Authors:  Shivany Gnaneswaran; Rebecca Deans; Richard J Cohn
Journal:  Obstet Gynecol Int       Date:  2012-05-06

8.  Cryopreservation of ovarian tissue in pediatric patients.

Authors:  R Fabbri; R Vicenti; M Macciocca; G Pasquinelli; M Lima; I Parazza; V Magnani; S Venturoli
Journal:  Obstet Gynecol Int       Date:  2012-02-13

9.  Effect of Previous Chemotherapy on the Quality of Cryopreserved Human Ovarian Tissue In Vitro.

Authors:  Babak Asadi Azarbaijani; Mona Sheikhi; Irma C Oskam; Mirja Nurmio; Tiina Laine; Helena Tinkanen; Sirpa Mäkinen; Tom G Tanbo; Outi Hovatta; Kirsi Jahnukainen
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

Review 10.  Fertility-preserving treatment options in patients with malignant hematological diseases.

Authors:  Mert Küçük; Ali Zahit Bolaman; Irfan Yavaşoğlu; Gürhan Kadıköylü
Journal:  Turk J Haematol       Date:  2012-10-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.